Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

The Prognostic Significance of p16 and its Role as a Surrogate Marker for Human Papilloma Virus in Oral Squamous Cell Carcinoma: An Analysis of 281 Cases

CHRISTIAN DOLL, CLAUDIUS STEFFEN, BENEDICTA BECK-BROICHSITTER, MAXIMILIAN RICHTER, KONRAD NEUMANN, ANNE POHRT, PHILIPP LOHNEIS, ANNIKA LEHMANN, MAX HEILAND, CARMEN STROMBERGER, ANNEKATRIN COORDES, KORINNA JOHRENS and JAN-DIRK RAGUSE
Anticancer Research May 2022, 42 (5) 2405-2413; DOI: https://doi.org/10.21873/anticanres.15719
CHRISTIAN DOLL
1Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Oral and Maxillofacial Surgery, Berlin, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Christian.Doll@charite.de
CLAUDIUS STEFFEN
1Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Oral and Maxillofacial Surgery, Berlin, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BENEDICTA BECK-BROICHSITTER
1Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Oral and Maxillofacial Surgery, Berlin, Germany;
2Katharinenhospital Stuttgart, Department of Oral and Maxillofacial Surgery, Stuttgart, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAXIMILIAN RICHTER
1Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Oral and Maxillofacial Surgery, Berlin, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KONRAD NEUMANN
3Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biometry and Clinical Epidemiology, Berlin, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANNE POHRT
3Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biometry and Clinical Epidemiology, Berlin, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PHILIPP LOHNEIS
4Institute of Pathology, University of Cologne, Cologne, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANNIKA LEHMANN
5Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Pathology, Berlin, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAX HEILAND
1Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Oral and Maxillofacial Surgery, Berlin, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CARMEN STROMBERGER
6Vivantes Klinikum Neukölln, Department of Radiooncology and Radiotherapy, Berlin, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANNEKATRIN COORDES
7Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Otorhinolaryngology, Berlin, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KORINNA JOHRENS
8Institute of Pathology, Technische Universität Dresden, Dresden, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JAN-DIRK RAGUSE
9Department of Oral and Maxillofacial Surgery, Fachklinik Hornheide, Münster, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: This study analyzed the expression of p16 in a large cohort of patients suffering from oral squamous cell carcinoma (OSCC) who received initial surgical therapy in order to evaluate the prognostic significance of p16 expression and to analyze its value as a surrogate marker to determine human papilloma virus (HPV) status. Materials and Methods: Immunohistochemical staining of p16 was performed on tissue microarrays. Different expression levels of p16 (>25%; >50%; ≥70%) with a moderate to strong intensity were correlated with the clinical outcome. HPV DNA was analyzed by polymerase chain reaction (PCR). Results: A total of 281 patients were included in this study. The p16 expression obtained using the abovementioned three different cutoffs did not significantly influence 5-year overall survival (OS) (p=0.23; p=0.45; p=0.23) nor recurrence-free survival (RFS) (p=0.79; p=0.45; p=0.142). In univariate Cox regression analysis, the p16 expression level was not a risk factor for OS (HR=0.637; 95%CI=0.271-1.5; p=0.300) and RFS (HR=0.74; 95%CI=0.339-1.61; p=0.449). A total of 17 patients (6.0%) were p16 positive with a cutoff ≥70%. HPV DNA was found in 4/11 of these cases by PCR, resulting in a positive predictive value of 0.36. In patients receiving adjuvant radio(chemo)therapy, a significantly (p=0.042) longer OS was observed in patients with p16 expression greater than 25% vs. ≤25%. Conclusion: In comparison with OPSCC, (strong) p16 positivity is rare in OSCC; however, in patients receiving primary surgery with adjuvant radio(chemo)therapy, p16 expression is associated with a higher survival rate. In conjunction with prior studies, p16 does not seem to be a reliable surrogate marker for HPV infection in OSCC.

Key Words:
  • Oral squamous cell carcinoma
  • prognostic factors
  • p16
  • HPV
  • adjuvant therapy

In 2018, the worldwide incidence of oral cancer, including cancer of the lip, was approximately 355,000 cases, accounting for 1.9% of deaths of all cancer sites (1). Despite advances in diagnostic techniques and treatment, oral squamous cell carcinoma (OSCC) remains a global burden. OSCC is mainly caused by unhealthy lifestyles, including smoking, solely or in combination with alcohol, and chewing tobacco. The percentage of attributable cancer deaths in mouth and oropharynx cancers was 16% for alcohol abuse and 42% for smoking (2), demonstrating the influence of these risk factors. Consequently, these individual factors are responsible for regional peaks of OSCC, for example in India, where it represents one third of the total cancer burden (3).

Despite these traditional risk factors, the human papilloma virus (HPV) has been identified as a potential risk factor for OSCC. However, in contrast to oropharyngeal carcinomas (OPSCC), HPV in OSCC is still not well established, and it appears to play a subordinate role (4-8). To date, only a few studies have investigated the direct influence of HPV on OSCC. Variations of the prevalence are mainly caused by regional differences, with North America showing a higher prevalence of HPV in OSCC than Asia or Europe (9). However, many studies fail to separate OPSCC from OSCC (8).

HPV-associated carcinogenesis is mediated through the influence of oncoprotein E6 and E7 expression on cell cycle regulatory pathways, which leads to p16 protein accumulation (8, 10). Therefore, this protein is used as a surrogate marker and is commonly applied to evaluate HPV association in head and neck squamous cell carcinoma (11). However, while it is suitable for some authors in OSCC, there are contradictory opinions (5, 8, 12-14). Nonetheless, even independent of HPV, p16 expression was associated with a lower stage and longer disease-free survival in OSCC (15).

The aim of this study was to analyze the expression of p16 in a large cohort of patients diagnosed with OSCC with a focus on patients receiving primary surgery in order to evaluate the prognostic significance of p16 and to analyze its value as a surrogate marker to determine HPV status in OSCC.

Materials and Methods

Ethics statement. The Ethics Committee of the Faculty of Medicine Charité Berlin approved this study (EA2/028/15).

Data collection. We retrospectively analyzed the data of 281 patients diagnosed with primary OSCC between 2005 and 2011 who received initial surgical therapy at Charité – University Hospital Berlin, Germany. Tumor staging and grading was performed using the 7th edition of the American Joint Committee on Cancer (AJCC) Staging Manual (16). Treatment and follow-up were performed according to the German medical guidelines at the time of presentation. Overall survival (OS) and recurrence-free survival (RFS) were defined as previously described (17).

p16 analysis. Formalin-fixed paraffin-embedded tissue (FFPE) and the corresponding slides from patients with primary OSCC matching the inclusion criteria were collected from the archive of the Institute of Pathology, Charité - Universitätsmedizin Berlin, Germany. All tumor diagnoses were reviewed by an experienced pathologist for head and neck pathology (K.J.). The classification of carcinomas was performed according to the current WHO (WHO classification of head and neck tumors Lyon 2017) criteria. Hematoxylin and eosin (HE) staining of all of the blocks to be examined was performed in order to determine the tumor percentage for the current examinations.

Immunohistochemical staining was performed on tissue microarrays (TMAs). TMA construction was performed as previously described (17). The immunohistological staining was performed with the p16 antibody from Ventana (clone E6H4, CINtec Histology V-Kit) ready to use on Ventana platform BenchMark ULTRA IHC/ISH staining module with UltraView DAB procedure (Ventana Medical Systems Inc., Tuscon, AZ, USA). The intensity of staining (negative, weak, moderate, and strong) and the percentage of stained tumor cells were scored. In case of more than one tumor slide per patient, arithmetic means were calculated from the intensity and positivity values of these slides. Different expression levels of p16 (>25%; >50%; ≥70%) with a moderate to strong intensity were defined and correlated with clinical parameters. For surrogate marker analysis, the cutoff value for p16 was defined as at least 70% of all tumor cells showing nuclear expression with a moderate to strong intensity.

HPV detection and typing. If available, DNA was extracted from consecutive sections of formalin-fixed paraffin embedded tumor specimens using Maxwell RSC DNA FFPE Kit, (Promega). HPV typing was performed using the HPV 3.5 LCD-Array Kit (Chipron GmbH, Germany) according to the manufacturer´s instructions. In brief, a primer mixture was used to generate biotinylated PCR products from a region of the L1 gene of the HPV genome. The PCR was performed under the following conditions: initial denaturation for 5 min at 95°C; followed by 45 cycles for 1 min at 94°C, 2 min at 45°C and 2 min at 72°C; and final elongation at 72°C for 7 min. PCR products were hybridized to HPV type-specific capture probes on the HPV 3.5 LCD-Array Kit, allowing the discrimination of HPV types 06, 11, 16, 18, 31, 33, 35, 39, 42, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 70, 72, 73, 81, 82, 83, 84, 90, and 91.

Statistical analysis. The data were collected in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) and analyzed using IBM (Armonk, NY, USA) SPSS Statistics Version 27 and R Version 4.0.3 (18). Categorical variables are presented as a frequency and percentage, while continuous variables are shown as mean values including standard deviations (SDs). The 5-year overall survival (OS) and relapse-free survival (RFS) were examined by the Kaplan– Meier method and log-rank test. Cox regression was used to identify prognostic factors for OS and RFS. All p-values are exploratory and reported without adjustment for multiple testing. p-Values smaller than α=0.05 were denoted as significant.

Results

A total of 281 patients (101 females; 180 males) with a mean age of 61.4 years (SD ±11.6; range=27-96 years) were included in this study. The mean follow-up for OS was 63.9 months (SD ±38.4). The cumulative 5-year OS of all patients was 63.3%. RFS was 54.1%.

p16 expression was analyzed in all patients and grouped according to three different cutoffs: >25% (N=27; 9.6%), >50% (N=22; 7.8%), and ≥70% (N=17, 6.0%). Typical pictures of p16 IHC staining are shown in Figure 1. The p16 expression using these cutoffs did not significantly influence 5-year OS (p=0.23; p=0.45; p=0.23) nor RFS (p=0.79; p=0.45; p=0.142) (Figure 2). In univariate Cox regression analysis, the p16 expression level was not a risk factor for OS (HR=0.637; 95%CI=0.271-1.5; p=0.300) and RFS (HR=0.74; 95%CI=0.339-1.61; p=0.449).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Immunohistochemical staining images of p16 in oral squamous cell carcinoma (OSCC). A) Weak cytoplasmic staining, the nuclei of the tumor cells are negative (black arrow); B) Strong nuclear staining (Table III, patient no. 2/HPV DNA PCR positive); C) Strong nuclear staining (Table III, patient no. 9 / HPV DNA PCR negative).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Kaplan–Meier curve showing overall survival of patients in relation to p16 expression ≥70% compared to <70%.

A total of 94 OSCC originated from the floor of the mouth (55 limited to the floor of mouth; 39 as the primary site with multilocular expansion). In these patients, RFS was significantly (p=0.045) longer in patients with an expression of p16 ≥ than 70% (N=10) compared to <70% (N=84). For OS, a strong tendency (p=0.072) was seen.

Subgroup analysis revealed a significantly (p=0.042) longer 5-year OS in patients receiving adjuvant radio(chemo)therapy with a p16 expression greater than 25% (N=6) compared to ≤25% (N=69) (Figure 3). There was no significant difference in RFS in this subgroup (p=0.059); however, a strong tendency was seen.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Kaplan–Meier curves showing overall survival of patients who received primary surgery and adjuvant radio(chemo)therapy in relation to p16 expression greater than 25% compared to ≤25%.

The clinicopathological characteristics of all patients receiving adjuvant radio(chemo)therapy with p16 expression greater than 25% (and moderate or strong intensity) are summarized in Table I.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Clinicopathological characteristics of all patients receiving adjuvant radio(chemo)therapy with p16 expression greater than 25%.

For surrogate marker analysis, the cutoff value for p16 was defined as at least 70% of all tumor cells showing expression with a moderate to strong intensity. As mentioned, a total of 17 patients of the 281 analyzed cases (6.0%) were p16-positive with a cutoff ≥70%. The clinicopathological characteristics are summarized in Table II. No significant correlation was found between patient- and tumor-related factors and p16 positivity.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Clinicopathological characteristics of all patients and patients with primary surgery grouped by p16-status (cutoff ≥70%).

A total of 14 p16-positive patients with a cutoff ≥70% were available for HPV DNA analysis using PCR (Table III). No amplification was observed in 3 cases. HPV DNA was found in 4 of 11 cases resulting in a positive predictive value (PPV) of 0.36.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Clinicopathological characteristics of all p16 positive (cutoff ≥70%) patients.

Discussion

Nowadays, it is broadly accepted that the proportion of head and neck cancers caused by HPV is increasing and that different molecular mechanisms are responsible for HPV- and non-HPV-related forms of the disease (19). However, head and neck cancers consist of a heterogeneous group of malignant tumors, and this connection appears to vary among different entities and might not be applicable to all tumors. Therefore, the present study focused on the homogeneous group of patients suffering from OSCC to evaluate the prognostic significance of p16 and its role as a surrogate marker for HPV in oral squamous cell carcinoma.

Studies evaluating the prevalence of HPV DNA in oral cancer show wide differences. A large meta-analysis published in 2014 found a pooled overall HPV DNA prevalence of 24.2% for the oral cavity (20). A more recent large international study published in 2016 including 1,264 oral cancer patients found a prevalence for HPV DNA of 7.4% (21). These authors observed geographical differences among the prevalence of HPV DNA, which might be one reason for the discordance with the aforementioned study. A large study from Germany published by Götz et al. evaluating HPV DNA showed a prevalence of 3.5% (8). Recently, a study from the Netherlands showed a prevalence of 2.2% in a cohort of 940 samples (7). Taken together, these lines of evidence indicate that, for OSCC, HPV appears to play a subordinate role in most patients.

In OPSCC, p16 expression in 70% or more of tumor cells with strong intensity shows a strong correlation with HPV (11, 22). Other authors use a cutoff level of greater than 75% expression with at least moderate intensity (23). Similar cutoffs are used by authors for non-oropharyngeal HNSCC; however, it is not clear whether the p16 scoring system is fully transferable (24) since the oral squamous epithelium is different from other sites of the head and neck area, including the oropharyngeal epithelium, as mentioned by other authors (7).

In the present study, p16 positivity for surrogate marker analysis was defined as at least 70% of all tumor cells showing nuclear expression with a moderate to strong intensity. A total of 17 patients (6.0%) of the evaluated 281 cases were p16 positive with a cutoff ≥70% in the present study. HPV DNA was found in 4 of 11 cases, resulting in a positive predictive value (PPV) of 0.36. This is comparable to other studies analyzing p16/HPV DNA exclusively in OSCC, although the exact criteria for p16 positivity/overexpression are not always mentioned and/or comparable.

A study published in Germany by Götz et al. showed that 12 of 202 cases (5.9%) were positive for p16 (with strong intensity). Of these, only 4 (33%) were positive for HPV (8). A large, international study published by Castellsagué et al. showed that 44/91 (48.4%) HPV DNA-positive oral cancers were p16 positive (21). In another study published in Thailand by Nopmaneepaisarn et al., only 9 out of 260 cases (3.5%) showed p16 positivity, with a poor predictive value for detecting HPV in OSCC (25). A higher expression of p16 was observed in oral cancer of a US population (26). A study from Hernandez et al. found an expression in 30% of tumors with a moderate or strong staining of p16 in equal to or greater than 70% of tumor cells (26). However, p16 was only positive in 9 out of 38 HPV DNA-positive tumors. A study from China published by Ni et al. showed p16 positivity in 14.3% (21/147) of cases using 25% as the cutoff value and 4.8% (7/147) using 75% as the cutoff value. However, only one patient was found to be HPV16 positive in the p16-positive patients (27). A recently published study by Nauta et al. showed that 46 of 580 (7.9%) OSCC cases were positive for p16. The study chose a cutoff value of ≥70% with strong and diffuse nuclear and cytoplasmic immunostaining. Of these, 21 cases (46%) were positive for HPV (7). These and other studies are summarized in Table IV. Taken together, these lines of evidence indicate that p16 seems not to be a reliable surrogate marker for HPV infection in OSCC, which is in line with the results of the present study.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Studies evaluating p16/HPV in oral squamous cell carcinoma (OSCC).

The p16 protein has prognostic significance in various cancers, including gastrointestinal stromal tumors (28), lung cancer (29, 30), vulvar (31), and cervical cancer (32). For instance, low p16 expression is associated with poor prognostic significance for survival in patients with non-small cell lung cancer (29). In contrast, p16 over-expression is associated with early relapse in patients with prostate cancer treated with radical prostatectomy (33). Among head and neck cancers, loss of p16 is associated with poor overall survival in nasopharyngeal carcinoma (34), and p16 over-expression leads to a significantly better prognosis in oropharyngeal cancer (35).

In the present study exclusively analyzing OSCC, we observed that p16 expression (cutoff >25%) in patients receiving primary surgery with adjuvant radio(chemo)therapy was associated with a better survival. The exact reason cannot be determined. Similar results for OSCC were described by Satgunaseelan et al. where p16 expression among the group of patients who received adjuvant radiotherapy was associated with a significantly longer disease-free and overall survival (15). This connection is also seen in oropharyngeal cancer (36), although the exact mechanism remains unclear.

Analyzing patient cohorts in general, Chen et al. found a poorer prognosis and a higher risk of tumor recurrence in OSCC without p16 expression in a Taiwanese cohort (37). A study from Germany published by Gröbe et al. found a significant correlation between p16 expression (differentiated whether p16 expression was negative, predominantly cytoplasmatic or nuclear) and recurrence-free survival (38). For OSCC of the buccal mucosa, Ni et al. found a longer RFS in p16 negative patients (27). Improved survival in p16 negative patients was also found in a Brazilian patient cohort (39). In the present study, p16 expression had no significant influence on RFS or OS concerning the whole patient cohort. Other studies have also shown no prognostic value of p16 for OSCC patients (7, 8, 26).

Many studies that have evaluated p16/HPV in head and neck cancer failed to discriminate the different entities of this heterogenous group of tumors. A particular strength of this study is the analysis of a homogeneous group of patients suffering from OSCC with a comparatively high number of patients included. The evaluation of HPV DNA by PCR in cases in which p16 was over-expressed showed that p16 is not a good surrogate marker for HPV infection in OSCC. However, our study had a few limitations. The data were collected retrospectively, and p16 expression was evaluated on tissue microarrays. The percentage of positive tumor cells of the TMA might not accurately reflect the whole tumor. Due to the fact that not all patients were evaluated for HPV DNA, the prevalence of HPV in our OSCC samples cannot be concluded from this study, and only the positive predictive value can be presented.

In conclusion, the results of this study show that p16 positivity is rare in OSCC; however, in patients receiving primary surgery with adjuvant radio(chemo)therapy, p16 expression is associated with supposedly better survival, as could also be shown with oropharyngeal tumors. Further studies with a larger cohort are necessary to confirm our results and to evaluate this pathomechanism. Our results support the literature showing that p16 does not seem to be a reliable surrogate marker for HPV infection in OSCC.

Acknowledgements

This study is part of the doctoral thesis of Maximilian Richter. The Authors thank Birgit Milluks for the great support.

Footnotes

  • Authors’ Contributions

    Author Contributions: Conceptualization/Design: JDR and KJ; Data collection/Investigation: MR, CD, AL; Statistical analysis: KN, AP and CD; Supervision: MH and BBB; Writing – original draft: CD and CS; Writing – review & editing: PL, CS and AC. All Authors contributed to the article and approved the submitted version.

  • Conflicts of Interest

    The Authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

  • Received February 13, 2022.
  • Revision received March 12, 2022.
  • Accepted March 14, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    1. Bray F,
    2. Ferlay J,
    3. Soerjomataram I,
    4. Siegel RL,
    5. Torre LA and
    6. Jemal A
    : Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6): 394-424, 2018. PMID: 30207593. DOI: 10.3322/caac.21492
    OpenUrlCrossRefPubMed
  2. ↵
    1. Danaei G,
    2. Vander Hoorn S,
    3. Lopez AD,
    4. Murray CJ,
    5. Ezzati M and Comparative Risk Assessment collaborating group (Cancers)
    : Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366(9499): 1784-1793, 2005. PMID: 16298215. DOI: 10.1016/S01406736(05)67725-2
    OpenUrlCrossRefPubMed
  3. ↵
    1. Krishna Rao SV,
    2. Mejia G,
    3. Roberts-Thomson K and
    4. Logan R
    : Epidemiology of oral cancer in Asia in the past decade – an update (2000-2012). Asian Pac J Cancer Prev 14(10): 5567-5577, 2013. PMID: 24289546. DOI: 10.7314/apjcp.2013.14.10.5567
    OpenUrlCrossRefPubMed
  4. ↵
    1. Belobrov S,
    2. Cornall AM,
    3. Young RJ,
    4. Koo K,
    5. Angel C,
    6. Wiesenfeld D,
    7. Rischin D,
    8. Garland SM and
    9. McCullough M
    : The role of human papillomavirus in p16-positive oral cancers. J Oral Pathol Med 47(1): 18-24, 2018. PMID: 29024035. DOI: 10.1111/jop.12649
    OpenUrlCrossRefPubMed
  5. ↵
    1. Kansy K,
    2. Thiele O and
    3. Freier K
    : The role of human papillomavirus in oral squamous cell carcinoma: myth and reality. Oral Maxillofac Surg 18(2): 165-172, 2014. PMID: 23242943. DOI: 10.1007/s10006-012-0383-0
    OpenUrlCrossRefPubMed
    1. Krüger M,
    2. Pabst AM,
    3. Walter C,
    4. Sagheb K,
    5. Günther C,
    6. Blatt S,
    7. Weise K,
    8. Al-Nawas B and
    9. Ziebart T
    : The prevalence of human papilloma virus (HPV) infections in oral squamous cell carcinomas: a retrospective analysis of 88 patients and literature overview. J Craniomaxillofac Surg 42(7): 1506-1514, 2014. PMID: 24947612. DOI: 10.1016/j.jcms.2014.04.022
    OpenUrlCrossRefPubMed
  6. ↵
    1. Nauta IH,
    2. Heideman DAM,
    3. Brink A,
    4. van der Steen B,
    5. Bloemena E,
    6. Koljenović S,
    7. Baatenburg de Jong RJ,
    8. Leemans CR and
    9. Brakenhoff RH
    : The unveiled reality of human papillomavirus as risk factor for oral cavity squamous cell carcinoma. Int J Cancer 149(2): 420-430, 2021. PMID: 33634865. DOI: 10.1002/ijc.33514
    OpenUrlCrossRefPubMed
  7. ↵
    1. Götz C,
    2. Drecoll E,
    3. Straub M,
    4. Bissinger O,
    5. Wolff KD and
    6. Kolk A
    : Impact of HPV infection on oral squamous cell carcinoma. Oncotarget 7(47): 76704-76712, 2016. PMID: 27732948. DOI: 10.18632/oncotarget.12501
    OpenUrlCrossRefPubMed
  8. ↵
    1. Lafaurie GI,
    2. Perdomo SJ,
    3. Buenahora MR,
    4. Amaya S and
    5. Díaz-Báez D
    : Human papilloma virus: An etiological and prognostic factor for oral cancer? J Investig Clin Dent 9(2): e12313, 2018. PMID: 29322686. DOI: 10.1111/jicd.12313
    OpenUrlCrossRefPubMed
  9. ↵
    1. de Abreu PM,
    2. Có ACG,
    3. Azevedo PL,
    4. do Valle IB,
    5. de Oliveira KG,
    6. Gouvea SA,
    7. Cordeiro-Silva MF,
    8. Louro ID,
    9. de Podestá JRV,
    10. Lenzi J,
    11. Sena A,
    12. Mendonça EF and
    13. von Zeidler SLV
    : Frequency of HPV in oral cavity squamous cell carcinoma. BMC Cancer 18(1): 324, 2018. PMID: 29580212. DOI: 10.1186/s12885-018-4247-3
    OpenUrlCrossRefPubMed
  10. ↵
    1. Prigge ES,
    2. Arbyn M,
    3. von Knebel Doeberitz M and
    4. Reuschenbach M
    : Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis. Int J Cancer 140(5): 1186-1198, 2017. PMID: 27859245. DOI: 10.1002/ijc.30516
    OpenUrlCrossRefPubMed
  11. ↵
    1. Ishibashi M,
    2. Kishino M,
    3. Sato S,
    4. Morii E,
    5. Ogawa Y,
    6. Aozasa K,
    7. Kogo M and
    8. Toyosawa S
    : The prevalence of human papillomavirus in oral premalignant lesions and squamous cell carcinoma in comparison to cervical lesions used as a positive control. Int J Clin Oncol 16(6): 646-653, 2011. PMID: 21528380. DOI: 10.1007/s10147-011-0236-0
    OpenUrlCrossRefPubMed
    1. Smeets SJ,
    2. Hesselink AT,
    3. Speel EJ,
    4. Haesevoets A,
    5. Snijders PJ,
    6. Pawlita M,
    7. Meijer CJ,
    8. Braakhuis BJ,
    9. Leemans CR and
    10. Brakenhoff RH
    : A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 121(11): 2465-2472, 2007. PMID: 17680565. DOI: 10.1002/ijc.22980
    OpenUrlCrossRefPubMed
  12. ↵
    1. Laco J,
    2. Nekvindova J,
    3. Novakova V,
    4. Celakovsky P,
    5. Dolezalova H,
    6. Tucek L,
    7. Vosmikova H,
    8. Vosmik M,
    9. Neskudlova T,
    10. Cermakova E,
    11. Hacova M,
    12. Sobande FA and
    13. Ryska A
    : Biologic importance and prognostic significance of selected clinicopathological parameters in patients with oral and oropharyngeal squamous cell carcinoma, with emphasis on smoking, protein p16(INK4a) expression, and HPV status. Neoplasma 59(4): 398-408, 2012. PMID: 22489695. DOI: 10.4149/neo_2012_052
    OpenUrlCrossRefPubMed
  13. ↵
    1. Satgunaseelan L,
    2. Virk SA,
    3. Lum T,
    4. Gao K,
    5. Clark JR and
    6. Gupta R
    : p16 expression independent of human papillomavirus is associated with lower stage and longer disease-free survival in oral cavity squamous cell carcinoma. Pathology 48(5): 441-448, 2016. PMID: 27370365. DOI: 10.1016/j.pathol.2016.03.015
    OpenUrlCrossRefPubMed
  14. ↵
    1. Edge SB,
    2. Byrd DR,
    3. Compton CC,
    4. Fritz AG,
    5. Greene FL and
    6. Trotti A
    (eds.): AJCC cancer staging manual. 7th edition. New York, NY, USA, Springer, 2010.
  15. ↵
    1. Doll C,
    2. Bestendonk C,
    3. Kreutzer K,
    4. Neumann K,
    5. Pohrt A,
    6. Trzpis I,
    7. Koerdt S,
    8. Dommerich S,
    9. Heiland M,
    10. Raguse JD and
    11. Jöhrens K
    : Prognostic significance of estrogen receptor alpha in oral squamous cell carcinoma. Cancers (Basel) 13(22): 5763, 2021. PMID: 34830915. DOI: 10.3390/cancers13225763
    OpenUrlCrossRefPubMed
  16. ↵
    1. R Core Team
    : R: A language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. Available at: https://www.R-project.org [Last accessed on March 3, 2022]
  17. ↵
    1. Kobayashi K,
    2. Hisamatsu K,
    3. Suzui N,
    4. Hara A,
    5. Tomita H and
    6. Miyazaki T
    : A review of HPV-related head and neck cancer. J Clin Med 7(9): 241, 2018. PMID: 30150513. DOI: 10.3390/jcm7090241
    OpenUrlCrossRefPubMed
  18. ↵
    1. Ndiaye C,
    2. Mena M,
    3. Alemany L,
    4. Arbyn M,
    5. Castellsagué X,
    6. Laporte L,
    7. Bosch FX,
    8. de Sanjosé S and
    9. Trottier H
    : HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 15(12): 1319-1331, 2014. PMID: 25439690. DOI: 10.1016/S1470-2045(14)70471-1
    OpenUrlCrossRefPubMed
  19. ↵
    1. Castellsagué X,
    2. Alemany L,
    3. Quer M,
    4. Halec G,
    5. Quirós B,
    6. Tous S,
    7. Clavero O,
    8. Alòs L,
    9. Biegner T,
    10. Szafarowski T,
    11. Alejo M,
    12. Holzinger D,
    13. Cadena E,
    14. Claros E,
    15. Hall G,
    16. Laco J,
    17. Poljak M,
    18. Benevolo M,
    19. Kasamatsu E,
    20. Mehanna H,
    21. Ndiaye C,
    22. Guimerà N,
    23. Lloveras B,
    24. León X,
    25. Ruiz-Cabezas JC,
    26. Alvarado-Cabrero I,
    27. Kang CS,
    28. Oh JK,
    29. Garcia-Rojo M,
    30. Iljazovic E,
    31. Ajayi OF,
    32. Duarte F,
    33. Nessa A,
    34. Tinoco L,
    35. Duran-Padilla MA,
    36. Pirog EC,
    37. Viarheichyk H,
    38. Morales H,
    39. Costes V,
    40. Félix A,
    41. Germar MJ,
    42. Mena M,
    43. Ruacan A,
    44. Jain A,
    45. Mehrotra R,
    46. Goodman MT,
    47. Lombardi LE,
    48. Ferrera A,
    49. Malami S,
    50. Albanesi EI,
    51. Dabed P,
    52. Molina C,
    53. López-Revilla R,
    54. Mandys V,
    55. González ME,
    56. Velasco J,
    57. Bravo IG,
    58. Quint W,
    59. Pawlita M,
    60. Muñoz N,
    61. de Sanjosé S,
    62. Xavier Bosch F and ICO International HPV in Head and Neck Cancer Study Group
    : HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst 108(6): djv403, 2016. PMID: 26823521. DOI: 10.1093/jnci/djv403
    OpenUrlCrossRefPubMed
  20. ↵
    1. Ang KK,
    2. Harris J,
    3. Wheeler R,
    4. Weber R,
    5. Rosenthal DI,
    6. Nguyen-Tân PF,
    7. Westra WH,
    8. Chung CH,
    9. Jordan RC,
    10. Lu C,
    11. Kim H,
    12. Axelrod R,
    13. Silverman CC,
    14. Redmond KP and
    15. Gillison ML
    : Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1): 24-35, 2010. PMID: 20530316. DOI: 10.1056/NEJMoa0912217
    OpenUrlCrossRefPubMed
  21. ↵
    1. van Gysen K,
    2. Stevens M,
    3. Guo L,
    4. Jayamanne D,
    5. Veivers D,
    6. Wignall A,
    7. Pang L,
    8. Guminski A,
    9. Lee A,
    10. Hruby G,
    11. Macleod P,
    12. Taylor A and
    13. Eade T
    : Validation of the 8th edition UICC/AJCC TNM staging system for HPV associated oropharyngeal cancer patients managed with contemporary chemo-radiotherapy. BMC Cancer 19(1): 674, 2019. PMID: 31288767. DOI: 10.1186/s12885-019-5894-8
    OpenUrlCrossRefPubMed
  22. ↵
    1. Chung CH,
    2. Zhang Q,
    3. Kong CS,
    4. Harris J,
    5. Fertig EJ,
    6. Harari PM,
    7. Wang D,
    8. Redmond KP,
    9. Shenouda G,
    10. Trotti A,
    11. Raben D,
    12. Gillison ML,
    13. Jordan RC and
    14. Le QT
    : p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol 32(35): 3930-3938, 2014. PMID: 25267748. DOI: 10.1200/JCO.2013.54.5228
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Nopmaneepaisarn T,
    2. Tangjaturonrasme N,
    3. Rawangban W,
    4. Vinayanuwattikun C,
    5. Keelawat S and
    6. Bychkov A
    : Low prevalence of p16-positive HPV-related head-neck cancers in Thailand: tertiary referral center experience. BMC Cancer 19(1): 1050, 2019. PMID: 31694600. DOI: 10.1186/s12885-019-6266-0
    OpenUrlCrossRefPubMed
  24. ↵
    1. Hernandez BY,
    2. Lynch CF,
    3. Chan OTM,
    4. Goodman MT,
    5. Unger ER,
    6. Steinau M,
    7. Thompson TD,
    8. Gillison M,
    9. Lyu C,
    10. Saraiya M and HPV Typing of Cancer Workgroup
    : Human papillomavirus DNA detection, p16INK4a, and oral cavity cancer in a U.S. population. Oral Oncol 91: 92-96, 2019. PMID: 30926069. DOI: 10.1016/j.oraloncology.2019.03.001
    OpenUrlCrossRefPubMed
  25. ↵
    1. Ni Y,
    2. Zhang X,
    3. Wan Y,
    4. Dun Tang K,
    5. Xiao Y,
    6. Jing Y,
    7. Song Y,
    8. Huang X,
    9. Punyadeera C and
    10. Hu Q
    : Relationship between p16 expression and prognosis in different anatomic subsites of OSCC. Cancer Biomark 26(3): 375-383, 2019. PMID: 31594213. DOI: 10.3233/CBM-192402
    OpenUrlCrossRefPubMed
  26. ↵
    1. Schneider-Stock R,
    2. Boltze C,
    3. Lasota J,
    4. Miettinen M,
    5. Peters B,
    6. Pross M,
    7. Roessner A and
    8. Günther T
    : High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 21(9): 1688-1697, 2003. PMID: 12721243. DOI: 10.1200/JCO.2003.08.101
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Tong J,
    2. Sun X,
    3. Cheng H,
    4. Zhao D,
    5. Ma J,
    6. Zhen Q,
    7. Cao Y,
    8. Zhu H and
    9. Bai J
    : Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures. Lung Cancer 74(2): 155-163, 2011. PMID: 21621871. DOI: 10.1016/j.lungcan.2011.04.019
    OpenUrlCrossRefPubMed
  28. ↵
    1. Pezzuto A,
    2. Cappuzzo F,
    3. D’Arcangelo M,
    4. Ciccozzi M,
    5. Navarini L,
    6. Guerrini S,
    7. Ricci A,
    8. D’Ascanio M and
    9. Carico E
    : Prognostic value of p16 protein in patients with surgically treated non-small cell lung cancer; relationship with Ki-67 and PD-L1. Anticancer Res 40(2): 983-990, 2020. PMID: 32014943. DOI: 10.21873/anticanres.14032
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Dohopolski MJ,
    2. Horne ZD,
    3. Pradhan D,
    4. Bhargava R,
    5. Edwards RP,
    6. Kelley JL,
    7. Comerci JT,
    8. Olawaiye AB,
    9. Courtney-Brooks M,
    10. Berger JL,
    11. Sukumvanich P and
    12. Beriwal S
    : The prognostic significance of p16 status in patients with vulvar cancer treated with vulvectomy and adjuvant radiation. Int J Radiat Oncol Biol Phys 103(1): 152-160, 2019. PMID: 30121234. DOI: 10.1016/j.ijrobp.2018.08.014
    OpenUrlCrossRefPubMed
  30. ↵
    1. Lin J,
    2. Albers AE,
    3. Qin J and
    4. Kaufmann AM
    : Prognostic significance of overexpressed p16INK4a in patients with cervical cancer: a meta-analysis. PLoS One 9(9): e106384, 2014. PMID: 25188353. DOI: 10.1371/journal.pone.0106384
    OpenUrlCrossRefPubMed
  31. ↵
    1. Henshall SM,
    2. Quinn DI,
    3. Lee CS,
    4. Head DR,
    5. Golovsky D,
    6. Brenner PC,
    7. Delprado W,
    8. Stricker PD,
    9. Grygiel JJ and
    10. Sutherland RL
    : Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res 7(3): 544-550, 2001. PMID: 11297246.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Mäkitie AA,
    2. MacMillan C,
    3. Ho J,
    4. Shi W,
    5. Lee A,
    6. O’Sullivan B,
    7. Payne D,
    8. Pintilie M,
    9. Cummings B,
    10. Waldron J,
    11. Warde P,
    12. Irish J,
    13. Brown D,
    14. Gilbert R,
    15. Gullane P,
    16. Liu FF and
    17. Kamel-Reid S
    : Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res 9(6): 2177-2184, 2003. PMID: 12796384.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Fischer CA,
    2. Kampmann M,
    3. Zlobec I,
    4. Green E,
    5. Tornillo L,
    6. Lugli A,
    7. Wolfensberger M and
    8. Terracciano LM
    : p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. Ann Oncol 21(10): 1961-1966, 2010. PMID: 20423915. DOI: 10.1093/annonc/mdq210
    OpenUrlCrossRefPubMed
  34. ↵
    1. Heiduschka G,
    2. Grah A,
    3. Oberndorfer F,
    4. Kadletz L,
    5. Altorjai G,
    6. Kornek G,
    7. Wrba F,
    8. Thurnher D and
    9. Selzer E
    : Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy. Strahlenther Onkol 191(3): 209-216, 2015. PMID: 25252603. DOI: 10.1007/s00066-014-0753-7
    OpenUrlCrossRefPubMed
  35. ↵
    1. Chen YW,
    2. Kao SY and
    3. Yang MH
    : Analysis of p16(INK4A) expression of oral squamous cell carcinomas in Taiwan: prognostic correlation without relevance to betel quid consumption. J Surg Oncol 106(2): 149-154, 2012. PMID: 22354873. DOI: 10.1002/jso.23067
    OpenUrlCrossRefPubMed
  36. ↵
    1. Gröbe A,
    2. Hanken H,
    3. Kluwe L,
    4. Schöllchen M,
    5. Tribius S,
    6. Pohlenz P,
    7. Clauditz T,
    8. Grob T,
    9. Simon R,
    10. Sauter G,
    11. Heiland M and
    12. Blessmann M
    : Immunohistochemical analysis of p16 expression, HPV infection and its prognostic utility in oral squamous cell carcinoma. J Oral Pathol Med 42(9): 676-681, 2013. PMID: 23721566. DOI: 10.1111/jop.12086
    OpenUrlCrossRefPubMed
  37. ↵
    1. De Jesus Oliveira Kato V,
    2. De Abreu MC,
    3. De Brito Kato AM,
    4. De Souza LL,
    5. Pontes FSC,
    6. De Castro Sant’anna C,
    7. GonÇalves A Jr.,
    8. Pontes HAR,
    9. Khayat AS and
    10. Burbano RMR
    : Significance of P16INK4A expression and PTEN loss of heterozygosity in human papilloma virus-related oral squamous cell carcinoma. Anticancer Res 40(11): 6355-6366, 2020. PMID: 33109573. DOI: 10.21873/anticanres.14656
    OpenUrlAbstract/FREE Full Text
    1. Mulder FJ,
    2. Klufah F,
    3. Janssen FME,
    4. Farshadpour F,
    5. Willems SM,
    6. de Bree R,
    7. Zur Hausen A,
    8. van den Hout MFCM,
    9. Kremer B and
    10. Speel EM
    : Presence of human papillomavirus and Epstein-Barr virus, but absence of merkel cell polyomavirus, in head and neck cancer of non-smokers and non-drinkers. Front Oncol 10: 560434, 2021. PMID: 33552950. DOI: 10.3389/fonc.2020.560434
    OpenUrlCrossRefPubMed
    1. Tokuzen N,
    2. Nakashiro KI,
    3. Tojo S,
    4. Goda H,
    5. Kuribayashi N and
    6. Uchida D
    : Human papillomavirus-16 infection and p16 expression in oral squamous cell carcinoma. Oncol Lett 22(1): 528, 2021. PMID: 34055093. DOI: 10.3892/ol.2021.12789
    OpenUrlCrossRefPubMed
    1. Blatt S,
    2. Pabst A,
    3. Zimmer S,
    4. Walter C,
    5. Al-Nawas B and
    6. Krüger M
    : Clinical efficacy of an antibody-based detection system for human papilloma virus infection in oral squamous cell carcinoma. Clin Oral Investig 25(5): 2837-2843, 2021. PMID: 33098030. DOI: 10.1007/s00784-020-03601-0
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (5)
Anticancer Research
Vol. 42, Issue 5
May 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Prognostic Significance of p16 and its Role as a Surrogate Marker for Human Papilloma Virus in Oral Squamous Cell Carcinoma: An Analysis of 281 Cases
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The Prognostic Significance of p16 and its Role as a Surrogate Marker for Human Papilloma Virus in Oral Squamous Cell Carcinoma: An Analysis of 281 Cases
CHRISTIAN DOLL, CLAUDIUS STEFFEN, BENEDICTA BECK-BROICHSITTER, MAXIMILIAN RICHTER, KONRAD NEUMANN, ANNE POHRT, PHILIPP LOHNEIS, ANNIKA LEHMANN, MAX HEILAND, CARMEN STROMBERGER, ANNEKATRIN COORDES, KORINNA JOHRENS, JAN-DIRK RAGUSE
Anticancer Research May 2022, 42 (5) 2405-2413; DOI: 10.21873/anticanres.15719

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
The Prognostic Significance of p16 and its Role as a Surrogate Marker for Human Papilloma Virus in Oral Squamous Cell Carcinoma: An Analysis of 281 Cases
CHRISTIAN DOLL, CLAUDIUS STEFFEN, BENEDICTA BECK-BROICHSITTER, MAXIMILIAN RICHTER, KONRAD NEUMANN, ANNE POHRT, PHILIPP LOHNEIS, ANNIKA LEHMANN, MAX HEILAND, CARMEN STROMBERGER, ANNEKATRIN COORDES, KORINNA JOHRENS, JAN-DIRK RAGUSE
Anticancer Research May 2022, 42 (5) 2405-2413; DOI: 10.21873/anticanres.15719
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • The Impact of Tonsillectomy on Oropharyngeal Cancer Development
  • Google Scholar

More in this TOC Section

  • CA9-Positive Keloid Fibroblasts: Modulator of Local Inflammation Induced by the Hypoxic and Glycolysis-enhanced Microenvironment
  • Predictive Factors for Multiple Metastases of Clear-cell Renal Cell Carcinoma
  • Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma Cells via Dual Inhibition of MAPK and PI3K/AKT/mTOR Pathways
Show more Experimental Studies

Similar Articles

Keywords

  • Oral squamous cell carcinoma
  • prognostic factors
  • p16
  • HPV
  • adjuvant therapy
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire